By Shaker A. Mousa
This useful assortment offers a complete replace on clinically proper in vitro and in vivo types of thrombosis and hemostasis for the invention and trying out of antithrombotics, and summarizes fresh improvement in prescription drugs for the prevention and therapy of assorted thromboembolic problems. issues of the 17 contributions contain low molecular weight heparins, antithrombotic medications for the therapy of heparin-induced thrombocytopenia, guidance for the prognosis of deep venous thrombosis and pulmonary embolism, the improvement of either small and big animal types, the features of issue Xa inhibitors, and the improvement of healing applicants in response to mobile adhesion molecules.
Read Online or Download Anticoagulants, Antiplatelets, and Thrombolytics PDF
Best medicine books
The Yearbook compiles the newest advancements in experimental and scientific learn and perform in a single finished reference booklet. The chapters are written by way of good well-known specialists within the box of in depth care and emergency drugs. it really is addressed to all people all for inner drugs, anesthesia, surgical procedure, pediatrics, extensive care and emergency medication.
- This Can't Happen To Me!: Tackling Type 2 diabetes
- Funding Health Sciences Research : a Strategy to Restore Balance.
- Atlas of Clinical Gross Anatomy
- Radioguided Surgery. Vandemecum
Additional info for Anticoagulants, Antiplatelets, and Thrombolytics
LMWHs were also shown to be as safe as UFH with respect to major bleeding complications, and as effective as UFH in preventing thromboembolic recurrences. Meta-analyses of trials evaluating enoxaparin, tinzaparin, dalteparin, and others in the treatment of DVT showed that LMWHs were likely to be more effective than UFH in the prevention of recurrent venous thromboembolism. LMWHs were also associated with a lower incidence of major bleeding and lower mortality rate in this clinical setting, particularly in patients with cancer.
Konstantopoulos, K. and Mousa, S. A. (2001) Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. Current Opinion in Investigational Drugs 2, 1086–1092. 9. Mousa, S. A. (1999) Antiplatelet therapies: recent advances in the development of platelet GPIIb/IIIa antagonists, in Current Interventional Cardiology Reports, Vol. 1. (Holmes, D. ), Current Science, Philadelphia, PA, pp. 243–252. 10. , et al. (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa inhibitors.
Moake, J. , Kamat, S. , Schafer, A. , Kleiman, N. , and McIntire, L. V. (1995) Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 91, 1354–1362. Mousa, S. , Abulencia, J. , McCarty, O. J. , Turner, N. , and Konstantopoulos, K. (2002) Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Anticoagulants, Antiplatelets, and Thrombolytics by Shaker A. Mousa